Conservative Thinkers Share Their Views for Biosimilars in a Post-ACA, BPCIA Landscape

Allison Inserro | The Center for Biosimilars

“Would legislators take the opportunity to redo some parts of the BPCIA, if they had the chance? Both [Alex] Brill and Hayes said while that, too, is theoretically possible—such as shortening the period of patent exclusivity or changing other aspects of the patent dance—the danger is that it would then get stuck in the quagmire of politics.”

Read Here